Highlights MedinCell S.A.

Equities

MEDCL

FR0004065605

Market Closed - Euronext Paris Other stock markets 11:35:13 2024-04-29 am EDT			5-day change	1st Jan Change
13.8 ^EUR	+9.00%		+19.38%	+91.67%

Apr. 17	Medincell: share price rises following agreement with AbbVie	CF
Apr. 16	Medincell, AbbVie to Co-Develop Injectable Therapeutics	DJ

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Medincell: share price rises following agreement with AbbVie	Apr. 17	CF
Medincell, AbbVie to Co-Develop Injectable Therapeutics	Apr. 16	DJ
Medincell Enters Into Strategic Co-development and Licensing Agreement with AbbVie to Develop Next-generation Long-acting Injectable Therapies	Apr. 16	CI
Medincell: Unitaid grant to combat malaria	Apr. 09	CF
Medincell Receives $6 Million Extension Grant from Unitaid for Malaria Drug Trial	Apr. 09	MT
Medincell S.A. Reaches Commercial Stage with the Market Launch by Teva of Uzedy? for the Treatment of Schizophrenia	Mar. 15	CI
Teva Pharmaceutical Industries Ltd. Announces Recruitment Completion of Phase 3 Clinical Study of mdc-TJK / Olanzapine Long-Acting Injectable	Jan. 09	CI
MedinCell S.A. Reports Earnings Results for the Half Year Ended September 30, 2023	Dec. 19	CI
Medincell Announces Successful Completion of Patient Enrollment in the Phase 3 Study of F14 (Mdc-Cwm), A First-In-Class Therapy for Localized Pain Relief After Total Knee Replacement	23-08-30	CI
MedinCell S.A. Reports Earnings Results for the Full Year Ended March 31, 2023	23-06-26	CI
Global markets live: HSBC, Logitech, Uber, IBM, BP...	23-05-02
Teva Pharmaceuticals and MedinCell Announce FDA Approval of UZEDY (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophrenia in Adults	23-04-28	CI
Medincell Announces Positive Results for the Saive Clinical Study in Prevention of Covid-19 Infection in A Contact-Based Population	23-01-05	CI
MedinCell S.A. Reports Earnings Results for the Half Year Ended September 30, 2022	22-12-06	CI
MedinCell Announces the Initiation of Phase 3 Study of F14 (mdc-CWM), A Therapeutic First-In-Class That Aims to Provide Weeks of Localized Pain Relief After Total Knee Replacement	22-11-07	CI
MedinCell Licenses Malaria Drug To United Nations-backed Public Health Group	22-09-14	MT
Medincell Signs Licence Agreement with the Medicines Patent Pool to Fight Malaria Transmission, as Part of Its Global Health Mission	22-09-13	CI
Teva Pharmaceuticals Announces Phase 3 Study to Be Initiated for Second Long-acting Injectable Antipsychotic Using MedinCell's Technology	22-08-29	CI
MedinCell S.A. Reports Earnings Results for the Full Year Ended March 31, 2022	22-06-14	CI
Teva and MedinCell Receive Complete Response Letter for TV-46000/mdc-IRM	22-04-19	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights MedinCell S.A.

Equities

MEDCL

FR0004065605

Highlights

Filters